ITGB2 and psoriasis: For instance, efalizumab, a humanized mAb against LFA-1, has shown some efficacy in the preclinical study and early stage of clinical trials for psoriasis treatment, but it has been halted because of the risk of progressive multifocal leukoencephalopathy.